MX9201110A - Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados. - Google Patents
Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados.Info
- Publication number
- MX9201110A MX9201110A MX9201110A MX9201110A MX9201110A MX 9201110 A MX9201110 A MX 9201110A MX 9201110 A MX9201110 A MX 9201110A MX 9201110 A MX9201110 A MX 9201110A MX 9201110 A MX9201110 A MX 9201110A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- sufferings
- hypoglycemia
- composition
- diabetes mellitus
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 230000002218 hypoglycaemic effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000013016 Hypoglycemia Diseases 0.000 title 1
- 102000055006 Calcitonin Human genes 0.000 abstract 2
- 108060001064 Calcitonin Proteins 0.000 abstract 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 2
- 229960004015 calcitonin Drugs 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporcionan métodos para el tratamiento de diabetes y otros estados que requieren de insulina, administrando insulina y una calcitonina con o sin amilina, y los métodos para el tratamiento de estados hipoglucémicos administrando una calcitonina sola o en combinación con glucagon y/o una amilina y composiciones relacionadas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/670,231 US5264372A (en) | 1991-03-15 | 1991-03-15 | Receptor-based screening methods for amylin agonists and antagonists |
| US70499591A | 1991-05-24 | 1991-05-24 | |
| US07/774,411 US5321008A (en) | 1991-01-10 | 1991-10-10 | Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9201110A true MX9201110A (es) | 1993-07-01 |
Family
ID=27418205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9201110A MX9201110A (es) | 1991-03-15 | 1992-03-13 | Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5321008A (es) |
| EP (1) | EP0533898B1 (es) |
| JP (1) | JPH05507943A (es) |
| AT (1) | ATE170401T1 (es) |
| AU (1) | AU648895B2 (es) |
| CA (1) | CA2082928C (es) |
| DE (1) | DE69226835T2 (es) |
| DK (1) | DK0533898T3 (es) |
| ES (1) | ES2122995T3 (es) |
| MX (1) | MX9201110A (es) |
| WO (1) | WO1992016222A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2077265A1 (en) * | 1991-01-10 | 1992-07-11 | Andrew Young | Amylin activity assays |
| US5234906A (en) * | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| US5814600A (en) * | 1991-05-24 | 1998-09-29 | Amylin Pharmaceuticals Inc. | Method and composition for treatment of insulin requiring mammals |
| US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US7101853B2 (en) * | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
| US7910548B2 (en) * | 1997-06-06 | 2011-03-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity |
| US5929055A (en) * | 1997-06-23 | 1999-07-27 | The Research Foundation Of State University Of New York | Therapeutic method for management of diabetes mellitus |
| JP4353544B2 (ja) * | 1998-01-09 | 2009-10-28 | アミリン・ファーマシューティカルズ，インコーポレイテッド | アミリン作動薬ペプチド用製剤 |
| US6936584B1 (en) | 1998-02-13 | 2005-08-30 | Amylin Pharmaceuticals, Inc. | Mixed amylin activity compounds |
| JP4372345B2 (ja) | 1998-02-13 | 2009-11-25 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 新規な混合アミリン活性化合物 |
| US7537795B2 (en) * | 2000-10-26 | 2009-05-26 | Alza Corporation | Transdermal drug delivery devices having coated microprotrusions |
| JP2006514990A (ja) * | 2002-12-27 | 2006-05-18 | ディオベックス， インコーポレイテッド | インスリン誘発性低血糖の予防および制御のための組成物および方法 |
| US7655618B2 (en) * | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| WO2004084859A2 (en) | 2003-03-21 | 2004-10-07 | Nastech Pharmaceutical Company Inc. | Nasal calcitonin formulations containing chlorobutanol |
| CN101001638A (zh) * | 2004-06-29 | 2007-07-18 | 迪奥贝克斯公司 | 用于预防和控制胰岛素诱发的低血糖的组合物和方法 |
| US20110152183A1 (en) * | 2008-06-25 | 2011-06-23 | Novo Nordisk A/S | Derivatised hybrid peptides of amylin and salmon calcitonin |
| CA2755068C (en) * | 2009-03-12 | 2018-11-06 | Nordic Bioscience A/S | Treatment of diabetes and metabolic syndrome |
| US11357829B2 (en) | 2017-02-03 | 2022-06-14 | Vanderbilt University | Systems, compositions and methods for treating diabetes |
| MX2021004185A (es) | 2018-10-11 | 2021-09-08 | Intarcia Therapeutics Inc | Polipeptidos analogos de la amilina humana y sus metodos de uso. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3171774D1 (en) * | 1980-03-31 | 1985-09-19 | Teijin Ltd | Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom |
| GB8720115D0 (en) * | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
| EP0348490B1 (en) * | 1988-01-11 | 1995-09-27 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
| DE69022501T2 (de) * | 1989-07-10 | 1996-02-01 | Amylin Pharmaceuticals Inc | Verwendung eines Amylinantagonisten zur Herstellung eines Artzneimittels zur Behandlung von Fettsucht und essentieller Hypertonie und damit zusammenhängenden Krankheiten. |
-
1991
- 1991-10-10 US US07/774,411 patent/US5321008A/en not_active Ceased
-
1992
- 1992-03-13 WO PCT/US1992/002191 patent/WO1992016222A1/en not_active Ceased
- 1992-03-13 ES ES92909629T patent/ES2122995T3/es not_active Expired - Lifetime
- 1992-03-13 MX MX9201110A patent/MX9201110A/es unknown
- 1992-03-13 EP EP92909629A patent/EP0533898B1/en not_active Expired - Lifetime
- 1992-03-13 CA CA002082928A patent/CA2082928C/en not_active Expired - Fee Related
- 1992-03-13 AT AT92909629T patent/ATE170401T1/de not_active IP Right Cessation
- 1992-03-13 DE DE69226835T patent/DE69226835T2/de not_active Expired - Fee Related
- 1992-03-13 AU AU16873/92A patent/AU648895B2/en not_active Ceased
- 1992-03-13 DK DK92909629T patent/DK0533898T3/da active
- 1992-03-13 JP JP92509074A patent/JPH05507943A/ja active Pending
-
1994
- 1994-06-10 US US08/259,755 patent/US5508260A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US5321008A (en) | 1994-06-14 |
| CA2082928C (en) | 2000-09-05 |
| DE69226835D1 (de) | 1998-10-08 |
| AU648895B2 (en) | 1994-05-05 |
| JPH05507943A (ja) | 1993-11-11 |
| EP0533898A4 (en) | 1993-10-13 |
| DE69226835T2 (de) | 1999-01-14 |
| US5508260A (en) | 1996-04-16 |
| WO1992016222A1 (en) | 1992-10-01 |
| CA2082928A1 (en) | 1992-09-16 |
| DK0533898T3 (da) | 1999-05-31 |
| EP0533898B1 (en) | 1998-09-02 |
| EP0533898A1 (en) | 1993-03-31 |
| AU1687392A (en) | 1992-10-21 |
| ATE170401T1 (de) | 1998-09-15 |
| ES2122995T3 (es) | 1999-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9201110A (es) | Composicion para el tratamiento de la diabetes mellitus, la hypoglicemia y de otros padecimientos relacionados. | |
| NO940436L (no) | Forlenget avgivelse av peptider | |
| CA2373266A1 (en) | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus | |
| BRPI0409600A (pt) | análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina | |
| EP0464022A4 (en) | Insulinotropic hormone | |
| ATE466028T1 (de) | N-terminal veränderte glp-1 abkömmlinge | |
| AR012998A1 (es) | Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente. | |
| AU3372595A (en) | Biologically active fragments of glucagon-like insulinotropic peptide | |
| CA2076658A1 (en) | Hyperglycemic compositions | |
| DE69327309D1 (de) | Verwendung eines peptids | |
| WO1999043705A8 (en) | N-terminally truncated glp-1 derivatives | |
| ES2150566T3 (es) | Tratamiento de la diabetes. | |
| AR022368A1 (es) | Procedimiento para administrar peptidos insulinotropicos | |
| UY26483A1 (es) | Activadores de la glucoquinasa transolefinica | |
| MY155219A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide | |
| PE108199A1 (es) | Composicion farmaceutica de tiazolidindiona y sulfonilurea | |
| AR013352A1 (es) | Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica. | |
| MY138246A (en) | Treatment of diabetes with thiazolidione and sulphonylurea. | |
| ATE491723T1 (de) | Neue verbindungen mit gemischter amylin aktivität | |
| ES2135353A1 (es) | Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones. | |
| ES2106169T3 (es) | Anticuerpos monoclonales especificos del cd4 y que no provocan agotamiento, destinados para el tratamiento de diabetes mellitus dependiente de insulina (idmm). | |
| BR0309375A (pt) | Tratamento de sìndrome metabólica | |
| MX9207555A (es) | Procedimiento mejorado para la reduccion durarera de depositos de grasa en el cuerpo, resistencia a la insulina, hiperinsulinemia e hiperglicemia en vertebrados. | |
| Service | Meal-related insulin requirements | |
| ECSP982591A (es) | Nuevo metodo de tratamiento iv |